DK1414961T3 - Nye oligoribonukleotid-derivater til målrettet inhibition af genekspression - Google Patents

Nye oligoribonukleotid-derivater til målrettet inhibition af genekspression

Info

Publication number
DK1414961T3
DK1414961T3 DK02758317T DK02758317T DK1414961T3 DK 1414961 T3 DK1414961 T3 DK 1414961T3 DK 02758317 T DK02758317 T DK 02758317T DK 02758317 T DK02758317 T DK 02758317T DK 1414961 T3 DK1414961 T3 DK 1414961T3
Authority
DK
Denmark
Prior art keywords
gene expression
targeted inhibition
derivatives
novel
oligoribonucleotide derivatives
Prior art date
Application number
DK02758317T
Other languages
Danish (da)
English (en)
Inventor
Eugen Uhlmann
Jochen Huber
Niki Gunkel
Sandra Neumann
Original Assignee
Sanofi Aventis Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis Deutschland filed Critical Sanofi Aventis Deutschland
Application granted granted Critical
Publication of DK1414961T3 publication Critical patent/DK1414961T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/318—Chemical structure of the backbone where the PO2 is completely replaced, e.g. MMI or formacetal
    • C12N2310/3183—Diol linkers, e.g. glycols or propanediols
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/319—Chemical structure of the backbone linked by 2'-5' linkages, i.e. having a free 3'-position
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
DK02758317T 2001-07-12 2002-07-05 Nye oligoribonukleotid-derivater til målrettet inhibition af genekspression DK1414961T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10133915A DE10133915A1 (de) 2001-07-12 2001-07-12 Neue Oligoribonucleotid-Derivate zur gezielten Hemmung der Genexpression
PCT/EP2002/007483 WO2003008595A2 (fr) 2001-07-12 2002-07-05 Derives d'oligoribonucleotide permettant l'inhibition orientee de l'expression genique

Publications (1)

Publication Number Publication Date
DK1414961T3 true DK1414961T3 (da) 2007-11-26

Family

ID=7691545

Family Applications (1)

Application Number Title Priority Date Filing Date
DK02758317T DK1414961T3 (da) 2001-07-12 2002-07-05 Nye oligoribonukleotid-derivater til målrettet inhibition af genekspression

Country Status (14)

Country Link
US (2) US20030105052A1 (fr)
EP (1) EP1414961B1 (fr)
JP (1) JP4690649B2 (fr)
AT (1) ATE371734T1 (fr)
AU (1) AU2002325305B2 (fr)
CA (1) CA2453295C (fr)
CY (1) CY1107776T1 (fr)
DE (2) DE10133915A1 (fr)
DK (1) DK1414961T3 (fr)
ES (1) ES2289131T3 (fr)
IL (2) IL159759A0 (fr)
MX (1) MXPA04000178A (fr)
PT (1) PT1414961E (fr)
WO (1) WO2003008595A2 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060009409A1 (en) 2002-02-01 2006-01-12 Woolf Tod M Double-stranded oligonucleotides
EP2213292B2 (fr) 2002-02-01 2016-06-22 Life Technologies Corporation Oligonucleotides double brin
US20030166282A1 (en) 2002-02-01 2003-09-04 David Brown High potency siRNAS for reducing the expression of target genes
US7803781B2 (en) * 2003-02-28 2010-09-28 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
DE10350256A1 (de) * 2003-10-01 2005-06-02 Grünenthal GmbH PIM-1-spezifische siRNA-Verbindungen
DE102004011687A1 (de) * 2004-03-10 2005-10-13 Grünenthal GmbH VGLUT-spezifische dsRNA-Verbindungen

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3717436A1 (de) * 1987-05-23 1988-12-08 Hoechst Ag Verfahren zur herstellung von doppelstraengiger dna
KR930016437A (ko) 1992-01-22 1993-08-26 귀틀라인, 슈미트 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도
US5886165A (en) * 1996-09-24 1999-03-23 Hybridon, Inc. Mixed backbone antisense oligonucleotides containing 2'-5'-ribonucleotide- and 3'-5'-deoxyribonucleotides segments
US6004804A (en) * 1998-05-12 1999-12-21 Kimeragen, Inc. Non-chimeric mutational vectors
US6010907A (en) * 1998-05-12 2000-01-04 Kimeragen, Inc. Eukaryotic use of non-chimeric mutational vectors
WO2000004189A1 (fr) * 1998-07-14 2000-01-27 Isis Pharmaceuticals, Inc. Oligonucleotides modifies

Also Published As

Publication number Publication date
EP1414961B1 (fr) 2007-08-29
CY1107776T1 (el) 2013-06-19
PT1414961E (pt) 2007-09-25
WO2003008595A3 (fr) 2004-01-22
ATE371734T1 (de) 2007-09-15
MXPA04000178A (es) 2004-03-18
US7635769B2 (en) 2009-12-22
CA2453295A1 (fr) 2003-01-30
IL159759A (en) 2012-05-31
EP1414961A2 (fr) 2004-05-06
AU2002325305B2 (en) 2007-05-17
IL159759A0 (en) 2004-06-20
JP4690649B2 (ja) 2011-06-01
DE50210819D1 (de) 2007-10-11
ES2289131T3 (es) 2008-02-01
US20060025374A1 (en) 2006-02-02
DE10133915A1 (de) 2003-02-06
CA2453295C (fr) 2012-09-25
US20030105052A1 (en) 2003-06-05
WO2003008595A2 (fr) 2003-01-30
JP2005500050A (ja) 2005-01-06

Similar Documents

Publication Publication Date Title
DK1409670T3 (da) Syntetiske dobbeltstrengede oligonukleorider til målrettet hæmning af genekspressionen
DK1261600T3 (da) Heteroaromatiske carboxamidderivater og deres anvendelse som inhibitorer af enzymet IKK-2
DE60217186D1 (de) Dpiv-inhibitoren auf glutaminbasis
BR0305258A (pt) Inibidores de polimerase de ns5b de hcv
DK1171417T3 (da) Fremgangsmåde til fremstilling af 3-aryloxy-3-arylpropylaminer og mellemprodukter deraf
MA26812A1 (fr) Pyrimidine-2,4,6-triones inhibitrices de metalloproteinases
BR9810870A (pt) Regulação de expressão de quinolato fosforibosil transferase
ATE390629T1 (de) Mikrophysiomessgerät
DE60138404D1 (de) Verbessertes system zur regulation der transgenexpression
AP2001002205A0 (en) Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase.
CY1107776T1 (el) Νεα παραγωγα ολιγο-νουκλεοτιδιων για στοχευμενη αναστολη της εκφρασης γονιδιων
BR9909819A (pt) Amida, uso de amidas, e, preparação farmacêutica para uso oral, parenteral ou intraperitoneal
HRP20050082A2 (en) 6-amino-1h-indazole and 4-aminobenzofuran compounds as phosphodiesterase 4 inhibitors
DE60229420D1 (de) Neue metallproteinaseinhibitoren
BR0111570A (pt) Inibidores de integrase de hiv
ATE287403T1 (de) 6-phenylbenzonaphthyidine
BR9711540A (pt) Inibidores de protease proteìnico estabilizados e variantes dos mesmos
RS20060196A (en) Imidazopyridine-derivatives as inducible no-synthase inhibitors
DK1347965T3 (da) Hidtil ukendte desloratidinsalte, fremgangsmåde til syntese deraf samt farmaceutiske præparater deraf
DK0975601T3 (da) Fremgangsmåde til fremstilling af butylthio-isoquinolin og mellemprodukter derfor
ATE327987T1 (de) Methylthiophencarboxanilide
AU2002325305A1 (en) Novel oligoribonucleotide derivatives for the targeted inhibition of gene expression
MXPA03012073A (es) Amidoderivados heterociclicos.
NO20024679D0 (no) Krystallinsk farmasöytikum
MXPA03010613A (es) Benzoilpirazoles substituidos con actividad herbicida.